Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

It's down 40% this year.

This company is in the midst of a major turnaround, but results have remained sluggish. Headwinds may subside this year, leading to strong earnings-per-share growth. The stock looks very attractive at ...

Each style of stock has its place in investor portfolios, though weighting may need to change with the economy.

LegalZoom presents a compelling buy-the-dip opportunity after a 10% post-earnings drop, despite strong results and raised guidance. LZ is shifting toward recurring subscription revenue, expanding its ...

Edwards Lifesciences remains a high-quality business with a wide economic moat , but the stock is still overvalued. Click ...